Education
About Us
Working with TipRanks
Follow Us
Intensity Therapeutics, Inc. (INTS)
NASDAQ:INTS
RESEARCH TOOLSreports
Top Page
Intensity Therapeutics, Inc.
(NASDAQ:INTS)
Rating:24Underperform
Price Target:―
Positive Factors
Clinical Trial Progress
DOR data bodes well for the Phase 3 sarcoma study.
Market Potential
The combination of improved safety, targeted therapy, and adaptive immune stimulus could enable INT230-6 to capture a significant portion of the solid tumor therapy market.
Treatment Innovation
Developing a disruptive treatment for solid tumors.
Negative Factors
Equity Offering
The company announced a registered direct equity offering with gross proceeds of approximately $3M.
Financial Performance
The company reported no revenues, and a net loss of $0.25 per diluted share, compared to our estimate of no revenues and a net loss of $0.16 per diluted share.
Intensity Therapeutics, Inc. (INTS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
N/A
Dividend YieldN/A
Average Volume (3M)334.56K
Price to Earnings (P/E)―
Beta (1Y)-0.21
Revenue GrowthN/A
EPS Growth-48.92%
CountryUS
Employees5
SectorHealthcare
Sector Strength43
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.22
Shares Outstanding18,398,203
10 Day Avg. Volume307,103
30 Day Avg. Volume334,564
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)2.70
Price to Sales (P/S)0.00
P/FCF Ratio-0.65
Enterprise Value/Market CapN/A
Enterprise Value/Revenue8.82
Enterprise Value/Gross Profit-622.05
Enterprise Value/Ebitda-0.12
Forecast
1Y Price Target
$4.00Price Target Upside952.63% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Intensity Therapeutics, Inc. Business Overview & Revenue Model
Company DescriptionIntensity Therapeutics, Inc. (INTS) is a clinical-stage biotechnology company focused on developing innovative cancer treatments. The company specializes in the research and development of immune-based therapies designed to enhance the effectiveness of existing anti-cancer treatments. Intensity Therapeutics aims to improve patient outcomes by utilizing its proprietary DfuseRxSM technology, which involves direct injection of therapeutic agents into tumors, thereby increasing the immune system's ability to combat cancer cells.
How the Company Makes MoneyIntensity Therapeutics, Inc. generates revenue primarily through partnerships, collaborations, and licensing agreements with pharmaceutical companies and research institutions. As a clinical-stage company, its revenue model is heavily reliant on securing funding through strategic alliances and collaborations that support its research and development activities. Additionally, the company may receive milestone payments and royalties upon successful commercialization of its therapies developed in collaboration with its partners. The company's financial success is contingent on the advancement of its drug candidates through clinical trials and eventual regulatory approval, which would enable it to license or co-develop its proprietary treatments with larger pharmaceutical companies.
Intensity Therapeutics, Inc. Financial Statement Overview
Summary
Intensity Therapeutics is in its development phase, typical of biotechnology firms, with no revenue generation yet. Negative profit margins and cash flow figures highlight financial challenges, though cash reserves offer short-term stability. The company is heavily reliant on external financing to support its R&D operations.Income Statement
Intensity Therapeutics has consistently reported zero revenue, indicating a company still in the development phase typical of biotechnology firms. The net profit margins are negative due to ongoing operational expenses without offsetting revenue. EBIT and EBITDA margins are also negative, highlighting the company's high expenditure relative to nonexistent revenue. Revenue and profit growth are absent, reflecting the company's pre-revenue stage.20
Very Negative
Balance Sheet
The company's balance sheet shows a low debt-to-equity ratio due to negative equity, which is typical for companies incurring losses during their R&D phase. Stockholders' equity is negative, indicating liabilities exceed assets. However, cash reserves are sufficient to cover immediate liabilities, which is a positive aspect for liquidity. The equity ratio is not a useful measure here given the negative equity.35
Negative
Cash Flow
Operating cash flow remains negative, reflecting the cash burn typical for biotech firms in R&D. There is no free cash flow growth due to ongoing operational losses. The financing activities indicate reliance on external funding to support operations. Cash flow ratios are not meaningful due to negative income and free cash flow.30
Negative
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
| 0.00 | -147.00K | -179.04K | 0.00 | 0.00 | EBIT |
| -16.59M | -8.32M | -7.63M | -8.01M | -6.22M | EBITDA |
| -16.24M | -10.09M | -7.40M | -7.88M | -6.03M | Net Income Common Stockholders |
| -16.27M | -10.54M | -7.45M | -7.89M | -5.96M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 2.59M | 14.78M | 1.31M | 4.54M | 9.32M | Total Assets |
| 4.78M | 17.30M | 1.76M | 5.22M | 10.15M | Total Debt |
| 138.00K | 158.00K | 4.49M | 2.34M | 497.48K | Net Debt |
| -2.45M | -8.40M | 3.18M | -2.20M | -8.82M | Total Liabilities |
| 1.86M | 4.13M | 16.85M | 13.90M | 11.71M | Stockholders Equity |
| 2.92M | 13.16M | -15.10M | -8.68M | -1.56M |
| Cash Flow | Free Cash Flow | |||
| -15.22M | -7.21M | -5.48M | -6.83M | -5.37M | Operating Cash Flow |
| -15.22M | -7.21M | -5.48M | -6.83M | -5.37M | Investing Cash Flow |
| 6.35M | -6.02M | 0.00 | 0.00 | 4.56M | Financing Cash Flow |
| 2.90M | 20.47M | 2.25M | 2.05M | 6.29M |
Intensity Therapeutics, Inc. Technical Analysis
Negative
0.38
Price Trends
1.37
Negative
1.80
Negative
2.62
Negative
Market Momentum
-0.28
Negative
16.59
Positive
25.01
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INTS, the sentiment is Negative. The current price of 0.38 is below the 20-day moving average (MA) of 0.52, below the 50-day MA of 1.37, and below the 200-day MA of 2.62, indicating a bearish trend. The MACD of -0.28 indicates Negative momentum. The RSI at 16.59 is Positive, neither overbought nor oversold. The STOCH value of 25.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for INTS.
Intensity Therapeutics, Inc. Risk Analysis
Intensity Therapeutics, Inc. disclosed 59 risk factors in its most recent earnings report. Intensity Therapeutics, Inc. reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
An investment in our common stock ("Common Stock") is speculative and involves a high risk, including a risk of your entire investment. You should carefully consider the risks described below and the other information in this Annual Report before buying shares in Intensity Therapeutics, Inc. These are risks and uncertainties that management believes are most likely to be material and therefore are important for an investor to consider. Our business operations and results may also be adversely affected by additional risks and uncertainties not presently known to us, or which are currently deemed immaterial, or which are similar to those faced by other companies in the pharmaceutical industry or business in general. If any of the following risks or uncertainties actually occurs, our business, financial condition, results of operations, or cash flows would likely suffer. In that event, the value of our stock could decline, perhaps significantly. Q4, 2024
2.
In addition, pricing and reimbursement for certain drugs will likely be significantly affected by the IRA drug price negotiation provisions (see "Risks Related to FDA and Foreign Regulatory Approval - If no product candidates using our technology are approved by the FDA or other regulatory body, third-party payors in the United States or anywhere will not reimburse the use of our product candidates. Even if approval is obtained, our products may become subject to inadequate reimbursement, unfavorable pricing regulations or healthcare reform initiatives, which may harm results of operations."). Q4, 2024
3.
Our employees, consultants and collaborators may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. Q4, 2024
Intensity Therapeutics, Inc. Peers Comparison
Overall Rating
UnderperformOutperform
Sector (53)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $5.14B | 3.06 | -43.57% | 2.81% | 16.81% | -0.12% | |
45 Neutral | $882.54K | ― | -89.21% | ― | -83.72% | 99.56% | |
45 Neutral | $4.33M | ― | -139.06% | ― | 80.00% | 86.70% | |
33 Underperform | $3.90M | ― | -233.77% | ― | ― | -97.16% | |
30 Underperform | $1.67M | ― | -300.16% | ― | ― | 79.57% | |
24 Underperform | ― | -298.57% | ― | ― | -48.92% |
* Healthcare Sector Average
Performance Comparison
INTS
Intensity Therapeutics, Inc.
0.36
-4.71
-92.90%
BDRX
Biodexa Pharmaceuticals
1.39
-26.11
-94.95%
TCRT
Alaunos Therapeutics
2.64
-8.16
-75.56%
SLRX
Salarius Pharmaceuticals
0.78
-3.01
-79.42%
ONCO
Onconetix
0.08
-5.58
-98.59%
Intensity Therapeutics, Inc. Corporate Events
Product-Related AnnouncementsBusiness Operations and Strategy
Intensity Therapeutics Highlights Cancer Treatment Progress
Positive
Apr 23, 2025
On April 22, 2025, Intensity Therapeutics, Inc. announced that it will post a presentation on its website, which may be used in meetings with various stakeholders. The presentation highlights the company’s ongoing clinical trials and product development, particularly focusing on INT230-6, a novel cancer treatment. The announcement underscores the company’s strategic positioning in the cancer treatment market, showcasing its robust intellectual property portfolio and partnerships with industry, government, and university hospitals. The release also notes the company’s cost-efficient business model and the potential benefits of its innovative technology in addressing challenges associated with traditional cancer therapies.
Spark’s Take on INTS Stock
According to Spark, TipRanks’ AI Analyst, INTS is a Underperform.
Intensity Therapeutics faces significant financial challenges typical of a pre-revenue biotech firm, with negative profit margins and reliance on external financing. Technical analysis indicates a bearish trend, with the stock trading below major moving averages. Valuation metrics are unfavorable due to the negative P/E ratio, typical of an early-stage biotech company. The overall score reflects these challenges, placing the stock at the lower end of the scoring range.
To see Spark’s full report on INTS stock, click here.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.